IRIS

A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.

Petrioli, R., Sabatino, M., Fiaschi, A.I., Marsili, S., Pozzessere, D., Messinese, S., et al. (2004). UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. BRITISH JOURNAL OF CANCER, 90(2), 306-309 [10.1038/sj.bjc.6601521].

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer

CIVITELLI, SERENELLA;TANZINI, GABRIELLO;TANI, FRANCESCO;MARZOCCA, GIUSEPPE;LORENZI, MARCO;GIORGI, GIORGIO;FRANCINI, GUIDO
2004-01-01

Abstract

A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.
2004
BRITISH JOURNAL OF CANCER
Petrioli, R., Sabatino, M., Fiaschi, A.I., Marsili, S., Pozzessere, D., Messinese, S., et al. (2004). UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. BRITISH JOURNAL OF CANCER, 90(2), 306-309 [10.1038/sj.bjc.6601521].
1.1 Articolo in rivista
File in questo prodotto:
File Dimensione Formato  
UFT-leucovorin-2004.pdf

non disponibili

Tipologia: Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 78.9 kB
Formato Adobe PDF
  Visualizza/Apri   Richiedi una copia
78.9 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/3288
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo